S&P 500 7,811.54 +0.59%Nasdaq 27,366.17 +0.64%Dow 51,654.95 +0.83%Russell 2000 2,806.98 +0.46%as of 2026-10-09 close
▚ The MicroCap Herald
Micro-cap and nano-cap intelligence, before the crowd
Uplistings & IPOs

BioStem Technologies Graduates to Nasdaq as the Small-Cap Listing Window Stays Open

The Florida tissue-allograft maker began trading on the Nasdaq Capital Market on August 7, joining a 2026 new-listings calendar that is running ahead of last year's pace.
Illustrative photograph: laboratory research equipment.

BioStem Technologies Inc. completed one of the more consequential milestones available to an OTC-traded company last week: a move up to a national exchange. The Pompano Beach, Florida-based regenerative medicine firm began trading on the Nasdaq Capital Market on Friday, August 7, keeping its existing ticker BSEM, after Nasdaq approved its listing application, according to the company's announcement carried by GlobeNewswire and StockTitan.

BioStem develops, manufactures and commercializes perinatal tissue allograft products — wound-care and clinical-use grafts derived from birth tissue — processed with its proprietary BioRetain, CryoTek and SteriTek technologies. Its portfolio spans brands including Neox, Clarix, VENDAJE and American Amnion, and the company holds accreditation from the American Association of Tissue Banks along with compliance with federal good tissue practice and good manufacturing practice standards, per the announcement.

Chairman and chief executive Jason Matuszewski framed the uplisting as recognition of the company's operational progress, saying he expects the Nasdaq listing to broaden access to capital and improve market visibility. Those are the standard arguments for graduating from over-the-counter markets: exchange listings open the door to institutional investors whose mandates bar OTC securities, typically tighten bid-ask spreads, and make index inclusion possible. StockTitan data pegged BioStem's market capitalization at roughly $68 million with a public float of about 13.3 million shares — squarely micro-cap territory, but with the governance and reporting standards a Nasdaq listing requires.

The company's own disclosures temper the enthusiasm. Its forward-looking statements enumerate risks that include maintaining Nasdaq compliance, competition, physician adoption of its products, and constraints on future fundraising — the routine caveats of a small medical-products company, but ones that matter for a stock this size.

BioStem's move lands in a broadly constructive environment for new and upgraded listings. Through August 10, 225 companies had completed US IPOs in 2026, about 6.6% ahead of the same point last year, according to data compiled by StockAnalysis. The first week of August alone brought a cluster of small and mid-sized debuts, including biotechs BlossomHill Therapeutics (BLSM) at $16 and Latigo Biotherapeutics (LTGO) at $18 on August 7, and Braveheart Bio (BRVE), which priced at $18 on August 6 and was recently quoted near $30, per StockAnalysis.

The calendar's small end also shows its characteristic dispersion. Ticketplus Ltd. (TP), an August 7 debut priced at $8, was recently quoted at $7, and several sub-$10 offerings from earlier in the year have fared far worse — one, GCDT, was down roughly 89% from its $4 offer price, per StockAnalysis. Blank-check vehicles continue to launch alongside operating companies, with two special-purpose acquisition units pricing at the standard $10 in the same week.

For the OTC ecosystem, uplistings like BioStem's are the aspirational path that hundreds of quoted companies cite in their investor materials, though few complete the journey in any given year. The process requires meeting Nasdaq's initial listing standards on price, equity and governance — hurdles that have prompted many candidates to execute reverse splits or capital raises first. BioStem's transition required no shareholder action, and its shares simply migrated venues under the same symbol.

Whether the listing translates into the liquidity and institutional sponsorship management is hoping for will take quarters, not days, to judge. But with the IPO tape running ahead of last year and micro-cap indices coming off an exceptionally strong twelve months, companies positioned to make the jump are finding the window open — and BioStem is the latest to step through it.

Sources & further reading

This article is for general information only and is not investment advice. Figures are as reported by the cited sources at time of writing.

Related coverage

Illustrative photograph: an industrial manufacturing facility.
Uplistings & IPOs

Chilwa Minerals Added a Nasdaq Listing With a US$3.5 Million ADS Offering at $5.60, Netting About US$2.5 Million for a Malawi Explorer Whose June 30 Cash Stood at A$1.1 Million

The ASX-listed Malawi heavy-mineral-sands explorer sold 625,000 American Depositary Shares with matching five-year warrants through Maxim Group, began trading as CHWM on Oct. 1 and closed Oct. 2. Its prospectus estimates about US$2.5 million net and flags going-concern doubt if more capital is not raised.

Imogen Farrow · October 10, 2026
Illustrative photograph: laboratory research equipment.
Uplistings & IPOs

Retension Pharmaceuticals Priced 3.75 Million Shares at $12.00 for Its Nasdaq Debut, Upsized From 3.3 Million, With a Going-Concern Paragraph in Its Audit and One Drug in Phase 2b

The Falls Church, Virginia hypertension-drug developer priced at the midpoint of its $11-$13 range and lifted the share count, for about $38.9 million net. Its prospectus discloses $13.5 million of cash at June 30, a going-concern qualification on the 2025 audit and no product revenue.

Imogen Farrow · October 10, 2026
Illustrative photograph: a retail store interior.
Uplistings & IPOs

Greene Concepts' Regulation A Amendment Was Qualified Sept. 30; Five Days Later It Priced the Remaining Units at $0.0025 a Share, Below Both Its Oct. 2 Close of $0.011 and Its Own Stated Book Value of $0.06

The OTCID-quoted bottler, which completed a 1-for-80 reverse split on July 30, is offering up to 2,357,500 units of 100 shares each for $589,375 in gross proceeds under Tier 1 of Regulation A. The circular reports $29,552 of cash at April 30, substantial doubt about going-concern status, and 6 billion shares that could be issued on conversion of 60 Series B preferred shares.

Imogen Farrow · October 10, 2026